دورية أكاديمية
Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer.
| العنوان: | Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer. |
|---|---|
| المؤلفون: | Rashid G; Department of Amity Medical School, Amity University, Gurugram, India., Khan NA; Department of Biosciences, Jamia Millia Islamia, Central University, New Delhi, India., Elsori D; Faculty of Resillience, Deans Office Rabdan Academy, Abu Dhabi, United Arab Emirates., Rehman A; Department of Biotechnology, Shri Mata Vaishno Devi University, Katra, India., Tanzeelah; Department of Biochemistry, University of Kashmir, Srinagar, India., Ahmad H; Department of Biochemistry, Faculty of Life Sciences, AMU, Aligarh, India., Maryam H; Department of Biochemistry, Faculty of Life Sciences, AMU, Aligarh, India., Rais A; Department of Biochemistry, Faculty of Life Sciences, AMU, Aligarh, India., Usmani MS; The Department of Surgery, Faculty of Medicine, JNMCH, AMU, Uttar Pradesh, India., Babker AM; Department of Medical Laboratory Sciences, Gulf Medical University, Ajman, United Arab Emirates., Kamal MA; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia., Hafez W; Department of Internal Medicine, NMC Royal Hospital, Abu Dhabi, United Arab Emirates.; The Medical Research Division, Department of Internal Medicine, The National Research Center, Ad Doqi, Egypt. |
| المصدر: | Frontiers in medicine [Front Med (Lausanne)] 2023 Mar 06; Vol. 10, pp. 1130710. Date of Electronic Publication: 2023 Mar 06 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2014]- |
| مستخلص: | Colorectal cancer is a sporadic, hereditary, or familial based disease in its origin, caused due to diverse set of mutations in large intestinal epithelial cells. Colorectal cancer (CRC) is a common and deadly disease that accounts for the 4 th worldwide highly variable malignancy. For the early detection of CRC, the most common predictive biomarker found endogenously are KRAS and ctDNA/cfDNA along with SEPT9 methylated DNA. Early detection and screening for CRC are necessary and multiple methods can be employed to screen and perform early diagnosis of CRC. Colonoscopy, an invasive method is most prevalent for diagnosing CRC or confirming the positive result as compared to other screening methods whereas several non-invasive techniques such as molecular analysis of breath, urine, blood, and stool can also be performed for early detection. Interestingly, widely used medicines known as non-steroidal anti-inflammatory drugs (NSAIDs) to reduce pain and inflammation have reported chemopreventive impact on gastrointestinal malignancies, especially CRC in several epidemiological and preclinical types of research. NSAID acts by inhibiting two cyclooxygenase enzymes, thereby preventing the synthesis of prostaglandins (PGs) and causing NSAID-induced apoptosis and growth inhibition in CRC cells. This review paper majorly focuses on the diversity of natural and synthetic biomarkers and various techniques for the early detection of CRC. An approach toward current advancement in CRC detection techniques and the role of NSAIDs in CRC chemoprevention has been explored systematically. Several prominent governing mechanisms of the anti-cancer effects of NSAIDs and their synergistic effect with statins for an effective chemopreventive measure have also been discussed in this review paper. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Rashid, Khan, Elsori, Rehman, Tanzeelah, Ahmad, Maryam, Rais, Usmani, Babker, Kamal and Hafez.) |
| References: | Lancet. 2010 Aug 28;376(9742):687-97. (PMID: 20728210) Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531. (PMID: 35505243) J Intern Med. 2021 Apr;289(4):493-507. (PMID: 32929813) J Clin Oncol. 2006 Nov 20;24(33):5313-27. (PMID: 17060676) World J Nephrol. 2015 Feb 6;4(1):57-73. (PMID: 25664247) Eur J Cancer. 2000 Mar;36(5):664-74. (PMID: 10738133) Acta Oncol. 2020 Mar;59(3):284-290. (PMID: 31769323) Hum Mol Genet. 2021 Oct 1;30(R2):R206-R224. (PMID: 34329396) Oncol Lett. 2016 Nov;12(5):3229-3233. (PMID: 27899987) J Intern Med. 2022 Oct;292(4):557-574. (PMID: 35585779) J Immunother Cancer. 2022 Jun;10(6):. (PMID: 35728872) BMJ Open. 2018 Jul 7;8(7):e021869. (PMID: 29982219) Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759) Braz J Otorhinolaryngol. 2022 Dec 28;:. (PMID: 36682990) Aliment Pharmacol Ther. 2005 Feb 15;21(4):321-39. (PMID: 15709983) Clin Chem Lab Med. 2019 Dec 18;58(1):3-10. (PMID: 30956227) Oncotarget. 2016 Nov 22;7(47):77683-77695. (PMID: 27765911) Ann Intern Med. 2017 Jan 03;166(1):37-51. (PMID: 27802478) Adv Biol Regul. 2015 Jan;57:130-46. (PMID: 25465296) Nat Rev Cancer. 2011 Feb;11(2):123-34. (PMID: 21258396) JAMA. 2021 May 18;325(19):1978-1998. (PMID: 34003220) World J Gastroenterol. 2016 Feb 7;22(5):1745-55. (PMID: 26855534) Cancer Res. 2006 Apr 15;66(8):4542-6. (PMID: 16618783) Int J Mol Sci. 2022 Jan 13;23(2):. (PMID: 35055034) J Mol Diagn. 2013 Jul;15(4):498-507. (PMID: 23747112) Ann Intern Med. 2017 Jan 3;166(1):58-68. (PMID: 27802508) Dis Colon Rectum. 2019 Apr;62(4):491-497. (PMID: 30844973) Semin Oncol. 2005 Feb;32(1):3-10. (PMID: 15726501) Int J Med Sci. 2020 Apr 27;17(8):1095-1101. (PMID: 32410839) Cancer Lett. 2020 Mar 31;473:50-61. (PMID: 31899298) Cell. 2000 Oct 13;103(2):311-20. (PMID: 11057903) J Oral Pathol Med. 2015 Mar;44(3):167-77. (PMID: 24527773) Gland Surg. 2020 Aug;9(4):1102-1111. (PMID: 32953625) Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1158-66. (PMID: 27197301) Cells. 2021 Jun 13;10(6):. (PMID: 34199169) Prostaglandins Other Lipid Mediat. 2015 Jul;120:91-6. (PMID: 26093284) Pharmgenomics Pers Med. 2018 May 16;11:83-94. (PMID: 29844697) Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8. (PMID: 10377455) Int J Mol Sci. 2020 Jul 27;21(15):. (PMID: 32726923) Cancer Prev Res (Phila). 2011 Oct;4(10):1655-64. (PMID: 21914855) Sci Rep. 2017 Jun 8;7(1):3032. (PMID: 28596563) Curr Protoc Pharmacol. 2017 Mar 17;76:9.23.1-9.23.17. (PMID: 28306150) Biomed Res Int. 2018 Mar 11;2018:2176056. (PMID: 29713641) JAMA. 2017 Jun 20;317(23):2402-2416. (PMID: 28632866) ACS Sens. 2020 Jun 26;5(6):1567-1572. (PMID: 32456420) BMJ Open. 2020 Aug 13;10(8):e037945. (PMID: 32796021) Oncogene. 2012 Nov 29;31(48):4979-86. (PMID: 22286762) Oncogene. 2008 Apr 17;27(18):2648-55. (PMID: 18059344) Glob J Health Sci. 2015 Nov 17;8(6):256-66. (PMID: 26755479) J Gastrointest Cancer. 2016 Jun;47(2):143-51. (PMID: 26922358) Front Pharmacol. 2019 Mar 05;10:152. (PMID: 30890933) Nat Rev Cancer. 2016 Mar;16(3):173-86. (PMID: 26868177) Nature. 2008 Jul 24;454(7203):428-35. (PMID: 18650913) Cancer Manag Res. 2018 Oct 26;10:4653-4667. (PMID: 30464589) J Natl Cancer Inst. 2015 Jun 24;107(9):. (PMID: 26109217) Curr Pharmacol Rep. 2015 Oct 1;1(5):295-301. (PMID: 26688785) Am J Gastroenterol. 2017 Oct;112(10):1509-1525. (PMID: 28786406) Adv Clin Chem. 2015;72:171-204. (PMID: 26471083) World J Gastroenterol. 2018 Jul 14;24(26):2818-2832. (PMID: 30018477) Gastroenterology. 2006 Dec;131(6):1674-82. (PMID: 17087947) J Natl Cancer Inst. 2016 Aug 16;108(12):. (PMID: 27530657) Cancers (Basel). 2020 Dec 09;12(12):. (PMID: 33317113) Int J Mol Epidemiol Genet. 2016 Sep 30;7(3):105-114. (PMID: 27766137) Oncoimmunology. 2015 May 26;4(11):e1039764. (PMID: 26451313) Nat Rev Cancer. 2002 Feb;2(2):133-42. (PMID: 12635176) PLoS One. 2014 Dec 31;9(12):e114633. (PMID: 25551641) Br J Cancer. 2022 Nov;127(10):1735-1743. (PMID: 35764787) Int J Mol Sci. 2022 Jan 27;23(3):. (PMID: 35163356) Int J Mol Sci. 2018 Aug 08;19(8):. (PMID: 30096840) Korean J Fam Med. 2022 Mar;43(2):101-108. (PMID: 35320895) Chem Rev. 2020 Aug 12;120(15):7592-7641. (PMID: 32609495) Carcinogenesis. 2015 Dec;36(12):1572-9. (PMID: 26449252) Hematol Oncol Clin North Am. 2022 Jun;36(3):393-414. (PMID: 35501176) Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. (PMID: 31455888) Pharmaceuticals (Basel). 2018 Oct 11;11(4):. (PMID: 30314310) Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. (PMID: 33198517) J Lipid Res. 2009 Apr;50 Suppl:S29-34. (PMID: 18952571) Cancer. 2018 Jul 1;124(13):2785-2800. (PMID: 29786848) Lancet. 2018 Aug 4;392(10145):387-399. (PMID: 30017552) FEBS Lett. 2005 Aug 15;579(20):4213-8. (PMID: 16051228) Nat Rev Cancer. 2021 Oct;21(10):655-668. (PMID: 34489588) World J Gastrointest Oncol. 2018 Jan 15;10(1):15-22. (PMID: 29375744) Cancer Sci. 2019 Oct;110(10):3018-3026. (PMID: 31361372) Cancer Biol Ther. 2020 Aug 2;21(8):667-674. (PMID: 26218314) Endoscopy. 2020 Aug;52(8):687-700. (PMID: 32572858) Gut. 2014 Nov;63(11):1755-9. (PMID: 24488498) Biomedicines. 2017 Jul 18;5(3):. (PMID: 28718829) Ann Surg Oncol. 2017 May;24(5):1165-1173. (PMID: 28008574) Indian J Surg Oncol. 2018 Dec;9(4):440-441. (PMID: 30538369) Ann Surg. 2016 Oct;264(4):575-84. (PMID: 27471839) Front Med (Lausanne). 2015 Mar 10;2:11. (PMID: 25806371) Genes Environ. 2016 Apr 01;38:6. (PMID: 27350826) Am J Gastroenterol. 2020 Dec;115(12):1940-1949. (PMID: 32773458) World J Gastroenterol. 2014 Jun 14;20(22):6786-808. (PMID: 24944469) Diagnostics (Basel). 2021 Mar 18;11(3):. (PMID: 33803735) CA Cancer J Clin. 2018 May;68(3):217-231. (PMID: 29485237) Oncol Lett. 2016 Oct;12(4):2329-2336. (PMID: 27698796) Crit Rev Oncol Hematol. 2021 Mar;159:103224. (PMID: 33493632) CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. (PMID: 26742998) Cancers (Basel). 2020 Aug 04;12(8):. (PMID: 32759723) Arch Intern Med. 2000 Aug 14-28;160(15):2363-8. (PMID: 10927735) PLoS One. 2021 Jan 19;16(1):e0245581. (PMID: 33465114) Int J Mol Sci. 2020 Nov 27;21(23):. (PMID: 33260951) J Natl Cancer Inst. 2017 Sep 1;109(9):. (PMID: 28376154) Cancers (Basel). 2021 Feb 03;13(4):. (PMID: 33546238) Cancer Causes Control. 2015 Mar;26(3):377-86. (PMID: 25537738) Int J Epidemiol. 2007 Oct;36(5):951-7. (PMID: 17921195) N Engl J Med. 2014 Apr 3;370(14):1287-97. (PMID: 24645800) BMC Gastroenterol. 2022 Apr 18;22(1):191. (PMID: 35436855) Clin Cancer Res. 2014 Mar 1;20(5):1104-13. (PMID: 24311630) Cancer Cell Int. 2015 Nov 05;15:106. (PMID: 26549987) Gastric Cancer. 2020 Sep;23(5):811-823. (PMID: 32215766) Pharmacol Res. 2022 Nov;185:106506. (PMID: 36241001) Blood. 2018 Apr 19;131(16):1777-1789. (PMID: 29519806) Cancers (Basel). 2021 Apr 22;13(9):. (PMID: 33922197) Cancer Biol Ther. 2022 Dec 31;23(1):446-461. (PMID: 35905195) BMJ Open. 2021 Sep 6;11(9):e045961. (PMID: 34489268) JAMA. 2018 May 8;319(18):1914-1931. (PMID: 29801018) JAMA Netw Open. 2021 Sep 1;4(9):e2122328. (PMID: 34473264) Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10. (PMID: 26166821) Cancers (Basel). 2023 Jan 22;15(3):. (PMID: 36765646) BMC Bioinformatics. 2021 Oct 25;22(Suppl 3):521. (PMID: 34696748) Drug Discov Today. 2020 Aug;25(8):1521-1527. (PMID: 32562844) Front Pharmacol. 2021 Jun 21;12:684162. (PMID: 34234675) Am J Physiol Gastrointest Liver Physiol. 2015 Jul 15;309(2):G59-70. (PMID: 26021807) J Clin Oncol. 2016 Jan 10;34(2):179-85. (PMID: 26438111) N Engl J Med. 2014 Apr 3;370(14):1298-306. (PMID: 24693890) Nefrologia. 2015 Nov-Dec;35(6):523-32. (PMID: 26474529) Br J Cancer. 2011 Oct 11;105(8):1107-13. (PMID: 21847126) PLoS One. 2018 Feb 23;13(2):e0192790. (PMID: 29474434) Nature. 2006 May 18;441(7091):362-5. (PMID: 16710422) Hum Genet. 2019 Apr;138(4):307-326. (PMID: 30820706) JAMA. 2022 Jun 7;327(21):2114-2122. (PMID: 35670788) Ann Intern Med. 2016 Jun 21;164(12):814-25. (PMID: 27064482) Cell Physiol Biochem. 2016;38(1):122-8. (PMID: 26741140) Asian Pac J Cancer Prev. 2015;16(4):1553-8. (PMID: 25743830) Fam Cancer. 2021 Jan;20(1):23-33. (PMID: 32507936) World J Gastroenterol. 2017 Jul 28;23(28):5086-5096. (PMID: 28811705) N Engl J Med. 2010 May 13;362(19):1795-803. (PMID: 20463339) Neoplasma. 2020 Mar;67(2):410-414. (PMID: 31884802) Cancer. 2014 Jan 1;120(1):35-42. (PMID: 24150925) HPB (Oxford). 2021 Feb;23(2):262-269. (PMID: 32675045) Br J Cancer. 2016 Oct 11;115(8):909-911. (PMID: 27657336) J Trauma Acute Care Surg. 2015 Sep;79(3):475-83. (PMID: 26307883) Asian Pac J Cancer Prev. 2015;16(17):7967-73. (PMID: 26625827) Postgrad Med. 2016;128(2):268-72. (PMID: 26753807) Med Clin North Am. 2019 Jan;103(1):111-123. (PMID: 30466668) J Clin Invest. 2005 Apr;115(4):959-68. (PMID: 15776112) Expert Rev Anticancer Ther. 2017 Dec;17(12):1131-1146. (PMID: 29022408) Cancers (Basel). 2022 Feb 06;14(3):. (PMID: 35159084) J Thorac Oncol. 2019 Mar;14(3):343-357. (PMID: 30529598) Stem Cells Int. 2016;2016:2048731. (PMID: 27882058) Biomedicines. 2020 Oct 13;8(10):. (PMID: 33066148) JAMA. 2015 Sep 8;314(10):1084. (PMID: 26348765) JMIR Public Health Surveill. 2022 Aug 16;8(8):e34589. (PMID: 35972778) Cell. 2015 Sep 10;162(6):1257-70. (PMID: 26343581) |
| فهرسة مساهمة: | Keywords: COX-pathways; KRAS; NSAIDs; biomarkers; chemoprevention; colonoscopy; colorectal cancer; statins |
| تواريخ الأحداث: | Date Created: 20230323 Latest Revision: 20230324 |
| رمز التحديث: | 20230324 |
| مُعرف محوري في PubMed: | PMC10025514 |
| DOI: | 10.3389/fmed.2023.1130710 |
| PMID: | 36950511 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2023.1130710 |